A top foundation is applauding the FDA for its approval of a Esketamine, a Ketamine nasal spray for certain people with treatment resistant depression.
Dr. Jeffrey Borenstein is a psychiatrist and President and CEO of the Brain and Behavior Research Foundation
He says the spray works quickly and is usually is used in conjunction with other medications.
Find out who should be checking out this new drug in our interview below.
Since 1996, BBRF has awarded 90 grants totaling more than$6.5 millionto fund research on rapid acting antidepressants conducted by scientists inthe United Statesand abroad. One of these scientists is BBRF Young InvestigatorCarla M. Canuso, M.D., of Johnson & Johnson/Janssen R&D, whose paper, "Esketamine Reduced Suicidal Thoughts Within Hours of Treatment" published in theAmerican Journal of PsychiatryinJuly 2018, was cited as one of the top 12 advances in psychiatric research from a BBRF-funded scientist in 2018. Among other scientists in the field who have received BBRF funding is Dr.Carlos A. Zarate, of the National Institutes of Mental Health, who was one of the early pioneers in the study of ketamine for the treatment of depression.
The Brain & Behavior Research Foundation
The Brain & Behavior Research Foundation awards research grants to develop improved treatments, cures, and methods of prevention for mental illness. These illnesses include addiction, ADHD, anxiety, autism, bipolar disorder, borderline personality disorder, depression, eating disorders, OCD, PTSD, and schizophrenia. Since 1987, the Foundation has awarded more than$394 millionto fund more than 4,700 leading scientists around the world, which has led to over$3.9 billionin additional funding. 100% of every dollar donated for research is invested in our research grants. The Foundation's operating expenses are covered by separate foundation grants.
For more information: The Brain & Behavior Research Foundation